三個皮匠報告
政策庫
new
付費
搜索

埃普奈明安全性數據-行業數據

埃普奈明安全性數據
埃普奈明安全性數據
埃普奈明在指南推薦中可聯用免疫調節劑，蛋白酶體抑制劑，糖皮質激素完成復發難治多發性骨髓瘤的治療。在復發治療更看重的安全性的情況下，埃普奈明在其 III 期臨床試驗過程中，不良反應多為血液學相關不良反應，肝毒性可逆轉，安全性良好。
其它 下載Excel 下載圖片 原圖定位
圖片屬性
圖片格式：PNG 圖片大?。?379KB 圖片尺寸：2350*2223
同報告圖片
 / 21
埃普奈明安全性數據_第1頁
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
埃普奈明安全性數據_第2頁
埃普奈明安全性數據_第3頁
埃普奈明安全性數據_第4頁
埃普奈明安全性數據_第5頁
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
埃普奈明安全性數據_第6頁
埃普奈明安全性數據_第7頁
埃普奈明安全性數據_第8頁
fCDlubTku70gfCDplIDllK7pop3vvIjnmb7kuIfnvo7lhYPvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS18CnwgMjAxOSB8IDMxICAgICAgICAgICAgICAgICAgIHwKfCAyMDIwIHwgNzYgICAgICAgICAgICAgICAgICAgfAp8IDIwMjEgfCA5OCAgICAgICAgICAgICAgICAgICB8CnwgMjAyMiB8IDEyMCAgICAgICAgICAgICAgICAgIHwKfCAyMDIzIHwgMTEyICAgICAgICAgICAgICAgICAgfAoK6LWE5paZ5p2l5rqQ77yaS2FyeW9waGFybeWumOe9keOAgeaLm+WVhuivgeWIuA==
埃普奈明安全性數據_第9頁
埃普奈明安全性數據_第10頁
埃普奈明安全性數據_第11頁
埃普奈明安全性數據_第12頁
埃普奈明安全性數據_第13頁
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
埃普奈明安全性數據_第14頁
埃普奈明安全性數據_第15頁
埃普奈明安全性數據_第16頁
埃普奈明安全性數據_第17頁
埃普奈明安全性數據_第18頁
埃普奈明安全性數據_第19頁
埃普奈明安全性數據_第20頁
埃普奈明安全性數據_第21頁
fCDlubTku70gfCDplIDllK7pop3vvIjkur/nvo7lhYPvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwKfCAyMDE1IHwgMCAgICAgICAgICAgICAgICB8CnwgMjAxNiB8IDYgICAgICAgICAgICAgICAgfAp8IDIwMTcgfCAxMiAgICAgICAgICAgICAgIHwKfCAyMDE4IHwgMjAgICAgICAgICAgICAgICB8CnwgMjAxOSB8IDMwICAgICAgICAgICAgICAgfAp8IDIwMjAgfCA0MiAgICAgICAgICAgICAgIHwKfCAyMDIxIHwgNjAgICAgICAgICAgICAgICB8CnwgMjAyMiB8IDgwICAgICAgICAgICAgICAgfAp8IDIwMjMgfCA5NyAgICAgICAgICAgICAgIHwKCui1hOaWmeadpea6kO+8muW8uueUn+WumOe9keOAgeaLm+WVhuivgeWIuA==
埃普奈明安全性數據_第22頁
所屬報告： 生物醫藥行業創新藥系列報告（八）：多發性骨髓瘤疾病深度多線治療用藥空間廣闊新機理藥物上市后放量迅速-240714（21頁）.pdf
打包全文圖表

相關數據

最新數據
聯系我們
  • 0731-84720580
  • sgpjbg002
  • 工作日 9:30 - 18:00
關于我們
侵權處理
關于我們

三個皮匠報告專業的行業報告下載站，每日更新，歡迎大家關注！

copyright@2008-2013 長沙景略智創信息技術有限公司版權所有
網站備案/許可證號：湘B2-20190120

客服
商務合作
小程序
服務號
折疊
午夜网日韩中文字幕,日韩Av中文字幕久久,亚洲中文字幕在线一区二区,最新中文字幕在线视频网站